[go: up one dir, main page]

RS54506B1 - Derivati pikolinamida kao inhibitori kinaza - Google Patents

Derivati pikolinamida kao inhibitori kinaza

Info

Publication number
RS54506B1
RS54506B1 RS20150730A RSP20150730A RS54506B1 RS 54506 B1 RS54506 B1 RS 54506B1 RS 20150730 A RS20150730 A RS 20150730A RS P20150730 A RSP20150730 A RS P20150730A RS 54506 B1 RS54506 B1 RS 54506B1
Authority
RS
Serbia
Prior art keywords
halo
kinase inhibitors
alkyl
cyclohexyl
substituents
Prior art date
Application number
RS20150730A
Other languages
English (en)
Inventor
Matthew T. Burger
Wooseok Han
Jiong Lan
Gisele Nishiguchi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41228825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS54506(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS54506B1 publication Critical patent/RS54506B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Jedinjenje Formule II, ili njegovi stereoizomer, tautomer ili farmaceutski prihvatljiva so,naznačen time, štoY može da bude cikloheksil, supstituisan jednim do tri supstituenta, gde su pomenuti supstituenti odabrani iz grupe koju čine hidroksil, amino, C1-4 alkil ili C1-4 halo alkil; gde R1 predstavlja vodonik, NH2 ili halo;gde R12 svaki za sebe predstavlja vodonik ili halo; igde je R5 izabran od cikloheksila, fenila i piridila, gde su navedeni cikloheksil, navedeni fenil i navedeni piridil svaki za sebe nezavisno supstituisani sa do tri supstituenta izabranih od halo, hidroksila, C1-4 alkila i C1-4 alkoksi. Prijava sadrži još 15 patentnih zahteva.
RS20150730A 2008-09-02 2009-08-31 Derivati pikolinamida kao inhibitori kinaza RS54506B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9366608P 2008-09-02 2008-09-02
US22566009P 2009-07-15 2009-07-15
PCT/EP2009/061205 WO2010026124A1 (en) 2008-09-02 2009-08-31 Picolinamide derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
RS54506B1 true RS54506B1 (sr) 2016-06-30

Family

ID=41228825

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20150730A RS54506B1 (sr) 2008-09-02 2009-08-31 Derivati pikolinamida kao inhibitori kinaza

Country Status (38)

Country Link
US (4) US8329732B2 (sr)
EP (1) EP2344474B1 (sr)
JP (2) JP5412519B2 (sr)
KR (1) KR101345920B1 (sr)
CN (3) CN104311480A (sr)
AU (1) AU2009289319C1 (sr)
BR (1) BRPI0918268B1 (sr)
CA (1) CA2734415C (sr)
CL (1) CL2011000454A1 (sr)
CO (1) CO6351725A2 (sr)
CR (1) CR20110114A (sr)
DK (1) DK2344474T3 (sr)
DO (1) DOP2011000067A (sr)
EA (1) EA020136B1 (sr)
EC (1) ECSP11010859A (sr)
ES (1) ES2551900T3 (sr)
GE (1) GEP20135849B (sr)
HN (1) HN2011000629A (sr)
HR (1) HRP20151410T1 (sr)
HU (1) HUE026381T2 (sr)
IL (1) IL211291A (sr)
MA (1) MA32684B1 (sr)
ME (1) ME01291A (sr)
MX (1) MX2011002365A (sr)
MY (1) MY150136A (sr)
NI (1) NI201100052A (sr)
NZ (1) NZ591449A (sr)
PE (1) PE20110298A1 (sr)
PL (1) PL2344474T3 (sr)
PT (1) PT2344474E (sr)
RS (1) RS54506B1 (sr)
SI (1) SI2344474T1 (sr)
SM (1) SMT201600005B (sr)
SV (1) SV2011003849A (sr)
TW (1) TWI434843B (sr)
UY (1) UY32085A (sr)
WO (1) WO2010026124A1 (sr)
ZA (1) ZA201101118B (sr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54181B9 (sr) 2005-12-13 2020-01-31 Incyte Holdings Corp Heteroaril supstituisani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
US20140249135A1 (en) * 2007-03-01 2014-09-04 Novartis Ag Pim kinase inhibitors and methods of their use
CN101932582B (zh) 2007-06-13 2013-09-25 因塞特公司 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
CA2735779A1 (en) * 2008-09-02 2010-03-11 Matthew Burger Bicyclic kinase inhibitors
EA020136B1 (ru) * 2008-09-02 2014-08-29 Новартис Аг Производные пиколинамида в качестве ингибиторов киназы
TWI484962B (zh) 2009-05-22 2015-05-21 Incyte Corp 作為ｊａｋ抑制劑之３－〔４－（７ｈ－吡咯并〔２，３－ｄ〕嘧啶－４－基）－１ｈ－吡唑－１－基〕辛烷或庚腈
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR101911697B1 (ko) 2010-03-10 2018-10-25 인사이트 홀딩스 코포레이션 Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
EA201290957A1 (ru) * 2010-04-07 2013-04-30 Ф.Хоффманн-Ля Рош Аг Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
KR102040479B1 (ko) 2010-05-21 2019-11-06 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
WO2012004217A1 (en) * 2010-07-06 2012-01-12 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
NZ611151A (en) 2010-11-19 2015-06-26 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012109749A1 (en) * 2011-02-14 2012-08-23 The Governors Of The University Of Alberta Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
UY33929A (es) * 2011-03-04 2012-10-31 Novartis Ag Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
EP2702063A1 (en) 2011-04-29 2014-03-05 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
US9458151B2 (en) * 2011-08-11 2016-10-04 Jikai Biosciences, Inc. Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
US9453003B2 (en) * 2011-08-11 2016-09-27 Jikai Biosciences, Inc. Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
JP6204462B2 (ja) * 2012-05-21 2017-09-27 ノバルティス アーゲー キナーゼ阻害剤としての新規環置換ｎ−ピリジニルアミド
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
WO2014033630A1 (en) 2012-08-31 2014-03-06 Novartis Ag Novel aminothiazole carboxamides as kinase inhibitors
UA119229C2 (uk) 2012-09-26 2019-05-27 Ф. Хоффманн-Ля Рош Аг Циклічні ефіри піразол-4-ілгетероциклілкарбоксамідних сполук та способи їх застосування
CN103724301A (zh) * 2012-10-10 2014-04-16 上海特化医药科技有限公司 (2r)-2-脱氧-2,2-二取代-1,4-核糖内酯及其制备方法和用途
BR112015010663B1 (pt) 2012-11-15 2022-12-06 Incyte Holdings Corporation Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
SG10201705662WA (en) 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
US9113629B2 (en) * 2013-03-15 2015-08-25 Dow Agrosciences Llc 4-amino-6-(4-substituted-phenyl)-picolinates and 6-amino-2-(4-substituted-phenyl)-pyrimidine-4-carboxylates and their use as herbicides
AU2014305989B2 (en) 2013-08-07 2019-11-28 Incyte Holdings Corporation Sustained release dosage forms for a JAK1 inhibitor
CA2917936A1 (en) * 2013-08-08 2015-02-12 Novartis Ag Pim kinase inhibitor combinations
CA2921959A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
AU2014354821A1 (en) * 2013-11-27 2016-05-26 Novartis Ag Combination therapy comprising an inhibitor of JAK, CDK and PIM
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
KR20160127140A (ko) 2014-03-18 2016-11-02 에프. 호프만-라 로슈 아게 옥세판-2-일-피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
JO3589B1 (ar) * 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA40035A (fr) 2014-10-14 2016-04-21 Dana Farber Cancer Inst Inc Molécules d'anticorps de pd-l1 et leurs utilisations
MX2017011597A (es) 2015-03-10 2018-05-11 Aduro Biotech Inc Composiciones y metodos para activar la señalizacion dependiente del "estimulador del gen de interferon".
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
CN105254624B (zh) * 2015-09-18 2019-08-09 上海吉铠医药科技有限公司 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
CN105130959B (zh) * 2015-09-18 2018-08-03 上海吉铠医药科技有限公司 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
JP7051692B2 (ja) 2015-11-03 2022-04-11 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ－１に特異的に結合する抗体及びその使用
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
CN107519175A (zh) * 2016-06-21 2017-12-29 上海方予健康医药科技有限公司 一种嘧啶化合物或其盐在制备用于预防和/或治疗与flt3相关的疾病或障碍的药物中的应用
CN107522695B (zh) * 2016-06-21 2018-09-14 上海方予健康医药科技有限公司 一种pim激酶抑制剂的盐酸盐及其制备方法和用途
CN107522696B (zh) 2016-06-21 2019-02-19 上海方予健康医药科技有限公司 一种嘧啶类化合物的盐酸盐及其制备方法和用途
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
JP7315483B2 (ja) * 2017-06-30 2023-07-26 ブリストル－マイヤーズ スクイブ カンパニー 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
LT3746429T (lt) 2018-01-30 2022-05-10 Incyte Corporation (1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
CA3095487A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
KR20200143454A (ko) 2018-04-13 2020-12-23 스미토모 다이니폰 파마 온콜로지, 인크. 골수증식성 신생물 및 암과 연관된 섬유증의 치료를 위한 pim 키나제 억제제
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
CN110078706B (zh) * 2019-05-31 2022-02-01 浙江师范大学 一种伊马替尼衍生物及其制备方法和用途
CN110452164B (zh) * 2019-09-10 2022-07-22 上海皓鸿生物医药科技有限公司 Pim447关键中间体的制备方法
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021091788A1 (en) * 2019-11-07 2021-05-14 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112915086B (zh) * 2021-01-27 2022-04-12 广州市力鑫药业有限公司 一种含有Akt靶向激酶抑制剂的药物组合物
BR112023018816A2 (pt) 2021-03-19 2023-10-31 Crinetics Pharmaceuticals Inc Antagonista do receptor de melanocortina subtipo-2 (mc2r) para o tratamento de doença
CN120302975A (zh) 2022-10-31 2025-07-11 住友制药美国公司 治疗骨髓增生性肿瘤的pim1抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2883301A (en) 2000-01-26 2001-08-07 Meiji Seika Kaisha Ltd. Novel carbapenem derivatives of quaternary salt type
JP2003520854A (ja) * 2000-01-27 2003-07-08 サイトビア インコーポレイテッド カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用
US8618085B2 (en) 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
PE20050444A1 (es) 2003-10-31 2005-08-09 Takeda Pharmaceutical Compuestos de piridina como inhibidores de la peptidasa
EP1694671A2 (en) 2003-12-04 2006-08-30 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20060004197A1 (en) 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
CR9465A (es) 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
EP1909910A1 (en) 2005-08-04 2008-04-16 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
AU2006302174B2 (en) 2005-10-06 2013-06-20 Exelixis, Inc. Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
HRPK20050957B3 (en) * 2005-11-11 2008-09-30 Džanko Nikša Collapsible hanger
US9206142B2 (en) * 2006-10-31 2015-12-08 Merck Sharp & Dohme Corp. Anilinopiperazine derivatives and methods of use thereof
JP4968860B2 (ja) * 2006-10-31 2012-07-04 シェーリング コーポレイション アニリノピペラジン誘導体およびアニリノピペラジン誘導体を使用する方法
EA019951B1 (ru) * 2007-03-01 2014-07-30 Новартис Аг Ингибиторы киназы pim и способы их применения
EP2178861B1 (en) * 2007-07-19 2014-08-20 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
JP5438680B2 (ja) 2007-09-10 2014-03-12 シプラ・リミテッド Ｒａｆキナーゼ阻害剤の製造方法及び該方法に使用する中間体
PE20091577A1 (es) * 2008-03-03 2009-11-05 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
EA020136B1 (ru) * 2008-09-02 2014-08-29 Новартис Аг Производные пиколинамида в качестве ингибиторов киназы
US8809380B2 (en) 2009-08-04 2014-08-19 Raqualia Pharma Inc. Picolinamide derivatives as TTX-S blockers
CA2824544A1 (en) 2011-01-21 2012-07-26 Anil Vasudevan Picolinamide inhibitors of kinases

Also Published As

Publication number Publication date
US20150315150A1 (en) 2015-11-05
NI201100052A (es) 2011-09-03
ME01291A (me) 2013-06-20
US20100056576A1 (en) 2010-03-04
HUE026381T2 (en) 2016-06-28
US8592455B2 (en) 2013-11-26
CN102203079A (zh) 2011-09-28
MY150136A (en) 2013-11-29
US20120134987A1 (en) 2012-05-31
TW201028393A (en) 2010-08-01
HN2011000629A (es) 2015-08-10
BRPI0918268A2 (pt) 2020-11-17
JP2012501314A (ja) 2012-01-19
ES2551900T3 (es) 2015-11-24
IL211291A (en) 2014-05-28
PE20110298A1 (es) 2011-05-21
KR20110048585A (ko) 2011-05-11
CL2011000454A1 (es) 2011-09-30
JP5813701B2 (ja) 2015-11-17
GEP20135849B (en) 2013-06-10
US9079889B2 (en) 2015-07-14
DOP2011000067A (es) 2017-01-15
PT2344474E (pt) 2015-12-28
SMT201600005B (it) 2016-02-25
AU2009289319C1 (en) 2013-12-05
ZA201101118B (en) 2011-09-28
MX2011002365A (es) 2011-04-04
JP2013231049A (ja) 2013-11-14
HK1156627A1 (en) 2012-06-15
SI2344474T1 (sl) 2015-12-31
HK1162022A1 (en) 2012-08-17
TWI434843B (zh) 2014-04-21
IL211291A0 (en) 2011-04-28
CN102203079B (zh) 2014-12-10
CA2734415A1 (en) 2010-03-11
BRPI0918268B1 (pt) 2021-08-03
EP2344474A1 (en) 2011-07-20
EP2344474B1 (en) 2015-09-23
CN103333157A (zh) 2013-10-02
ECSP11010859A (es) 2011-04-29
PL2344474T3 (pl) 2016-03-31
US20140079693A1 (en) 2014-03-20
DK2344474T3 (en) 2015-12-14
HRP20151410T1 (hr) 2016-01-15
NZ591449A (en) 2012-12-21
KR101345920B1 (ko) 2014-02-06
CR20110114A (es) 2011-05-10
SV2011003849A (es) 2011-07-07
CN104311480A (zh) 2015-01-28
MA32684B1 (fr) 2011-10-02
WO2010026124A1 (en) 2010-03-11
EA201100425A1 (ru) 2011-10-31
CO6351725A2 (es) 2011-12-20
UY32085A (es) 2010-03-26
EA020136B1 (ru) 2014-08-29
AU2009289319A1 (en) 2010-03-11
AU2009289319B2 (en) 2011-10-27
JP5412519B2 (ja) 2014-02-12
CA2734415C (en) 2016-07-26
US8329732B2 (en) 2012-12-11

Similar Documents

Publication Publication Date Title
RS54506B1 (sr) Derivati pikolinamida kao inhibitori kinaza
RS52166B (sr) Amino-heterociklična jedinjenja
RS52261B (sr) Amidofenoksi indazoli kao korisni inhibitori c-met-a
RS52964B (sr) Derivat 7-piperidinoalkil-3,4-dihidrokvinolona
RS53830B1 (sr) Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
RS51949B (sr) Inhibitori kinaze
MD4582B1 (ro) Derivaţi ai 1-fenil-1H-benzimidazolului ca inhibitori ai protein kinazei
MY177250A (en) Novel nicotinamide derivative or salt thereof
RS54202B1 (sr) Hinolin i hinoksalin derivati kao inhibitori kinaza
RS54260B1 (sr) Derivati aminodihidrotiazina kao bace inhibitori za tretman alzheimerove bolesti
EA201000113A1 (ru) Пиразольные соединения
NZ587051A (en) Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase)
RS54048B1 (sr) Paraziticidna jedinjenja dihidroizoksazola
RS53451B (sr) Inhibitori p70 s6 kinaze
RS53684B1 (sr) Modulatori prostaciklinskog (pgi2) receptora korisnih u tretmanu poremećaja vezanih za pgi2
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
ME01604B (me) Inhibitori p38 map kinaze
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
NZ710052A (en) Novel pyrazol derivatives
RS53588B1 (sr) Jedinjenja i kompozicije kao inhibitori protein kinaza
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
MX338209B (es) Derivados de benzoxaborol para tratar infecciones bacterianas.
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
MX2011009146A (es) Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acido aminonicotinico como inhibidores de dhodh.